Loading
Protein Degradation and Inhibitors / Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Medicinal Chemistry · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical medicinal chemistry study introducing HDTACs, a novel class of targeted protein degradation agents designed to exploit tumor hypoxia. Compound 11f showed selective degradation of EGFR and tumor growth inhibition in cell and mouse xenograft models, but the work remains at the proof-of-concept stage with no efficacy comparator, clinical data, or mechanistic validation of the ROS pathway.
Preclinical chemical synthesis and in vitro/in vivo proof-of-concept study. Cell lines and tumor-bearing animal models; no human subjects.. Intervention: Compound 11f, an HDTAC incorporating a hypoxia-activated group and EGFR ligand.
Compound 11f demonstrated potent degradation of target protein with remarkable hypoxia/normoxia selectivity in vitro Compound 11f achieved effective target protein degradation and significant tumor growth inhibition in vivo
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding is not yet suitable for clinical translation. The approach is conceptually novel but requires validation of selectivity, mechanism, toxicity, and efficacy against standard therapies before consideration for human study.
This is a proof-of-concept chemical synthesis and mechanism study demonstrating a novel drug design strategy in cells and xenografts, lacking clinical endpoints or comparison to standard therapy.
As stated by the source record.
This finding is not yet suitable for clinical translation. The approach is conceptually novel but requires validation of selectivity, mechanism, toxicity, and efficacy against standard therapies before consideration for human study.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy for treating cancers. Nevertheless, enhancing selectivity toward tumors remains a critical challenge. In this study, we designed and synthesized a series of hypoxia-activated degradation-targeting chimeras (HDTACs) by incorporating tumor hypoxia-activated groups (HAGs)─which generate reactive oxygen species (ROS) under tumor hypoxia conditions─into EGFR-based protein of interest (POI) ligands through appropriate linkers, leveraging the ability of ROS to induce protein degradation. Among the synthesized compounds, 11f demonstrated potent degradation of the target protein and remarkable hypoxia/normoxia selectivity in vitro, along with effective target protein degradation and significant tumor growth inhibition in vivo, thereby confirming the feasibility of the HDTAC strategy. This work presents an innovative TPD approach for cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.